<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="57360">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02359344</url>
  </required_header>
  <id_info>
    <org_study_id>1014802/101</org_study_id>
    <nct_id>NCT02359344</nct_id>
  </id_info>
  <brief_title>PK &amp; Tolerability of CNV1014802 in Young and Elderly Healthy Volunteers</brief_title>
  <official_title>A Randomized, Double-blind, Placebo Controlled, Two Period Crossover Study to Investigate the Pharmacokinetics, Tolerability and Cognitive Effects of an Oral Dose Regimen of 150mg Tid CNV1014802 in Healthy Young Versus Elderly Male and Female Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Convergence Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Parexel</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Convergence Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized, double-blind, placebo controlled, two period crossover study to investigate
      the pharmacokinetics, tolerability and cognitive effects of 8 days dosing of CNV1014802 in
      healthy young versus elderly male and female subjects. Treatment periods will be separated
      by 13 days. The primary outcome measures are pharmacokinetics (PK) and tolerability.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2015</start_date>
  <completion_date type="Anticipated">April 2015</completion_date>
  <primary_completion_date type="Anticipated">April 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Concentration</measure>
    <time_frame>9 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the concentration curve</measure>
    <time_frame>9 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Minimum concentration</measure>
    <time_frame>9 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of adverse events</measure>
    <time_frame>9 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in vital signs compared to baseline</measure>
    <time_frame>9 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in 12-lead ECG parameters compared to baseline</measure>
    <time_frame>9 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in safety lab parameters compared to baseline</measure>
    <time_frame>9 days</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Trigeminal Neuralgia</condition>
  <arm_group>
    <arm_group_label>CNV1014802</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CNV1014802 150mg tid 7 days plus a single dose on day 8</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tid 7 days plus a single dose on day 8</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CNV1014802</intervention_name>
    <arm_group_label>CNV1014802</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Healthy male and female over 18 years using acceptable methods of contraception

        Key Exclusion Criteria:

          -  Positive pre-study HIV, Hepatitis B surface antigen or positive Hepatitis C antibody

          -  History or evidence of alcohol or drug abuse

          -  Pregnant or lactating females

          -  Participation in a clinical trial within 3 months or the current study or exposure to
             more than four new chemical entities within 12 months.

          -  Use of prohibited concomitant medication

          -  History or presence of any clinically significant abnormality in vital signs / ECG /
             laboratory tests, or have any medical or psychiatric condition, which, in the opinion
             of the Investigator may interfere with the study procedures or compromise subject
             safety.

          -  Relevant history of a suicide attempt or suicidal behavior
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Medical Director</last_name>
    <email>info@convergencepharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Parexel International</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Recruitment</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>February 2015</verification_date>
  <lastchanged_date>February 9, 2015</lastchanged_date>
  <firstreceived_date>February 2, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Neuralgia</mesh_term>
    <mesh_term>Trigeminal Neuralgia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
